NIH to Launch Human Safety Study of Ebola Vaccine Candidate
​Initial human testing of an investigational vaccine to prevent Ebola virus disease will begin by the National Institute of Allergy and Infectious Diseases (NIAID). The early-stage trial will begin initial human testing of a vaccine co-developed by NIAID and GlaxoSmithKline and will evaluate the experimental vaccine’s safety and ability to generate an immune system response in healthy adults. [National Institute of Allergy and Infectious Diseases] Press Release